Ignite Creation Date:
2024-10-25 @ 7:48 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06554470
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-11
Brief Title:
Local vs Systemic Methotrexate in Management of Uterine Ectopic Pregnancy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Local Versus Systemic Methotrexate in Management of Uterine Ectopic Pregnancy A Randomized Trial
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to compare local and systemic methotrexate in the management of uterine ectopic pregnancy regarding the duration of beta human chorionic gonadotropin hCG clearance and need for further management options
Detailed Description:
Ectopic pregnancy is considered a life-threatening condition which requires immediate intervention Owing to the advancements in medical technology ectopic pregnancy can now be diagnosed in the early stages
Methotrexate MTX is an antimetabolite drug showing a competitive reversible binding concerning natural dihydrofolates and acting as an inhibitor of the dihydrofolate-reductase DHFR a key enzyme synthesizing the tetrahydrofolates needed for the synthesis of purine and pyrimidine rings
Methotrexate MTX is an antimetabolite drug showing a competitive reversible binding concerning natural dihydrofolates and acting as an inhibitor of the dihydrofolate-reductase DHFR a key enzyme synthesizing the tetrahydrofolates needed for the synthesis of purine and pyrimidine rings
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None